Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005057 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
A Phase 1 study of Melanoma (Skin), sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Study locations
NCT00005057: Completed Phase 1 study of Melanoma (Skin), sponsored by National Human Genome Research Institute (NHGRI).
NCT00005057 is a Phase 1 study of Melanoma (Skin) that has completed, run by National Human Genome Research Institute (NHGRI). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005057, a Phase 1 study of Melanoma (Skin), has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3
- Study locations
Study Summary
RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the cancer more sensitive to the antiviral agent ganciclovir. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have stage IV melanoma.
Conditions Studied
Interventions
- DRUG ganciclovir
- BIOLOGICAL adenovirus RSV-TK
Study Locations (3)
Maryland
- Clinical Genetherapy Branch - Bethesda
- Metabolism Branch - Bethesda
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-03 |
| Phase | Phase 1 |
What the finished NCT00005057 record still lists
NCT00005057 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 2 interventions - of which ganciclovir is the first listed.
NCT00005057 reports a single indexed study location in Maryland, Texas.
Frequently Asked Questions
What is clinical trial NCT00005057 about?
NCT00005057 is a clinical study titled "Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma". RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the cancer more sensitive to the antiviral agent ganciclovir. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have stage IV melanoma.
What is the current status of trial NCT00005057?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-03.
What conditions does trial NCT00005057 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT00005057?
The interventions under investigation include: ganciclovir (DRUG), adenovirus RSV-TK (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005057?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005057 being conducted?
This trial has 3 study locations across Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Biological Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia